A critical review of the use of carvedilol in ischemic heart disease

American Journal of Cardiovascular Drugs

Volumn 12, Issue 6, 2012, Pages 391-401

  Chen Scarabelli, Carol ^a,b   Saravolatz II, Louis ^b   Murad, Yahya ^b   Shieh, Wen Shi ^b   Qureshi, Waqas ^b   Di Rezze, Justin ^b   Abrencillo, Rodeo ^b   Gardin, Tova ^b   Gidwani, Umesh K ^c   Saravolatz, Louis ^b   Faggian, Giuseppe ^d   Scarabelli, Tiziano M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CALCIUM; CARVEDILOL; DRUG METABOLITE; FREE RADICAL; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; MAGNESIUM; METOPROLOL; NITRIC OXIDE; PHOSPHATE; PLACEBO; POTASSIUM; PROPANOL; SB 211475; SCAVENGER; SODIUM; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ALPHA ADRENERGIC RECEPTOR BLOCKING; AMBULATORY MONITORING; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BARE METAL STENT; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; EXERCISE; EXERCISE TOLERANCE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHY; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; MAGNESIUM BLOOD LEVEL; MITOSIS INHIBITION; MULTICENTER STUDY (TOPIC); NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SILENT MYOCARDIAL ISCHEMIA; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASODILATATION;

EID: 84870265067     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11636090-000000000-00000     Document Type: Review

References (71)

1. Fonarow GC. Role of carvedilol controlled-release in cardiovascular disease. Expert Rev Cardiovasc Ther 2009; 7 (5): 483-98
2. Feuerstein GZ, Ruffolo Jr RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl. F: 38-42
3. Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999; 137 (4 Pt 1): 646-52 (Pubitemid 29173576)
4. Feuerstein GZ, Bril A, Ruffolo Jr RR. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997; 80 (11A): 41L-45L (Pubitemid 27528446)
5. Brunvand H, Frłyland L, Hexeberg E, et al. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol 1996; 314 (1-2): 99-107 (Pubitemid 26378891)
6. Feuerstein GZ, Ruffolo Jr RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996; 17 Suppl. B: 24-9 (Pubitemid 26136857)
7. Nichols AJ, Sulpizio AC, Ashton DJ, et al. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989; 39 (5): 327-36 (Pubitemid 20011443)
8. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27 (5): 335-71 (Pubitemid 15107153)
9. Hansen O, Johansson BW, Nilsson-Ehle P, et al. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. J Cardiovasc Pharmacol 1994; 24 (6): 853-9
10. Feuerstein GZ, Yue TL, Cheng HY, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl 1993; 11 (4): S41-8 (Pubitemid 23226738)
11. Yue TL, Wang X, Gu JL, et al. Carvedilol, a new vasodilating betaadrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995; 273 (3): 1442-9
12. Brunvand H, Liu G, Ma XL, et al. SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. Eur J Pharmacol 1998; 356 (2-3): 193-8 (Pubitemid 28439131)
13. Bing OH. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994; 26 (8): 943-8
14. Teiger E, Than VD, Richard L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97 (12): 2891-7 (Pubitemid 26197104)
15. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992; 26 (5): 518-25
16. Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996; 277 (1): 128-36 (Pubitemid 27169052)
17. Drá biková K. On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo. Neuroendocrinol Lett 2006; 27 Suppl. 2: 138-40 (Pubitemid 46534357)
18. Yasunari K, Maeda K, Nakamura M, et al. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116 (7): 460-5 (Pubitemid 38388615)
19. Szajerski P, Zielonka J, Sikora A, et al. Radical scavenging and NO-releasing properties of selected beta-adrenoreceptor antagonists. Free Radic Res 2006 Jul; 40 (7): 741-2
20. Gomes A, Costa D, Lima JL, et al. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem 2006 Jul 1; 14 (13): 4568-77 (Pubitemid 43728661)
21. Oettl K, Greilberger J, ZanggerK, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001 Jul 15; 62 (2): 241-8 (Pubitemid 32522945)
22. Lopez BL, Christopher TA, Yue TL, et al. Carvedilol, a new betaadrenoreceptor blocker antihypertensive drug, protects against free-radicalinduced endothelial dysfunction. Pharmacology 1995 Sep; 51 (3): 165-73
23. Werns SW, Lucchesi BR. Free radicals and ischemic tissue injury. Trends Pharmacol Sci 1990; 11 (4): 161-6 (Pubitemid 20118010)
24. Yue TL, McKenna PJ, Ruffolo Jr RR, et al. Carvedilol, a new betaadrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992; 214 (2-3): 277-80
25. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 Nov 27; 288 (5789): 373-6 (Pubitemid 11169009)
26. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992; 262 (2 Pt 2): H611-5
27. Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb 1993; 13 (6): 771-6 (Pubitemid 23164678)
28. Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007; 20 (7): 777-83 (Pubitemid 46936169)
29. Nishioka K, Nakagawa K, Umemura T, et al. Carvedilol improves endothelium- dependent vasodilation in patients with dilated cardiomyopathy. Heart 2007; 93 (2): 247-8 (Pubitemid 46180307)
30. Hamburger SA, Barone FC, Feuerstein GZ, et al. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991; 43 (3): 113-20
31. Galderisi M, D'Errico A. Beta-blockers and coronary flow reserve: the importance of a vasodilatory action. Drugs 2008; 68 (5): 579-90 (Pubitemid 351451538)
32. Brunvand H, Kvitting PM, Rynning SE, et al. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol 1996; 28 (3): 409-17 (Pubitemid 26317440)
33. Hansen O, Johansson BW. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients. J Hypertens Suppl 1993; 11 (4): S55-60 (Pubitemid 23226740)
34. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. Circulation 1997; 96 (1): 183-91 (Pubitemid 27298420)
35. Dargie HJ. Design and methodology of the CAPRICORN trial: a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000 Sep; 2 (3): 325-32
36. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357 (9266): 1385-90 (Pubitemid 32455364)
37. Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004; 93 (9A): 13B-6B (Pubitemid 38624267)
38. Fonarow GC, Lukas MA, Robertson M, et al. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).AmHeart J 2007; 154 (4): 637-44 (Pubitemid 47429577)
39. Basu S, Senior R, Raftery EB, et al. The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. Eur Heart J 1996; 17 Suppl. F: 43-7 (Pubitemid 26411698)
40. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90 (13): 6189-93 (Pubitemid 23191480)
41. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21 (2): 221-7 (Pubitemid 23027597)
42. Sung CP, Arleth AJ, Eichman C, et al. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 1997; 283 (2): 910-7 (Pubitemid 27514654)
43. Cha KS, Kim MH, Kim JW, et al. Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. Am Heart J 2004 Feb; 147 (2): E7
44. Kim HK, Hong YJ, Jeong MH, et al. Two-year clinical outcome after carvedilol- loaded stent implantation in patients with coronary artery disease. Korean J Intern Med 2011 Mar; 26 (1): 41-6
45. Serruys PW, Foley DP, Höfling B, et al. Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation 2000 Apr 4; 101 (13): 1512-8 (Pubitemid 30180886)
46. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109 (2): 201-6 (Pubitemid 38114140)
47. Sutton MG,SharpeN. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101 (25): 2981-8 (Pubitemid 30415891)
48. Ono K, MatsumoriA, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98 (2): 149-56 (Pubitemid 28317895)
49. Li B, Liao YH, Cheng X, et al. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 2006 Aug 10; 111 (2): 247-55 (Pubitemid 44131484)
50. Dewald O, Zymek P, Winkelmann K, et al. CCL2/Monocyte Chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005; 96 (8): 881-9 (Pubitemid 40604972)
51. BergmanMR, Teerlink JR,MahimkarR, et al.Cardiacmatrixmetalloproteinase- 2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007; 292 (4): H1847-60 (Pubitemid 46572408)
52. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42 (8): 1446-53 (Pubitemid 37267288)
53. Cimmino G, Ibanez B, Giannarelli C, et al. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int J Cardiol 2011 Dec; 153 (3): 256-61
54. Tang YD. Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001; 23 (5): 476-80
55. van der Does R. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. Eur Heart J 1991; 12 (1): 60-4
56. Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. Clin Investig 1992; 70 Suppl. 1: S93-7
57. Wendt T, van der Does R, Schraeder R, et al. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S147-50
58. Lahiri A. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris.AmJ Cardiol 1987; 59 (8): 769-74 (Pubitemid 17061284)
59. Kaski JC, Rodriguez-Plaza L, Brown J, et al. Efficacy of carvedilol in exerciseinduced myocardial ischemia. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S137-40
60. Jamal SM, Freedman SB, Thomson A, et al. Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S141-6
61. Rodrigues EA, Lahiri A, Hughes LO, et al. Antianginal efficacy of carvedilol, a beta-blocking drugwith vasodilating activity.AmJCardiol 1986; 58 (10): 916-21 (Pubitemid 17175826)
62. Kishida H, Saito T, Fukuma N, et al. Evaluation of a new vasodilating betablocking agent, carvedilol, in exertional angina using holter monitoring. Jpn Heart J 1990; 31 (4): 449-60 (Pubitemid 20334407)
63. Storstein L. Carvedilol: clinical experience in arrhythmias. Cardiology 1993; 82 Suppl. 3: 29-33
64. Hogue Jr CW, Hyder ML. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 2000; 69 (1): 300-6 (Pubitemid 30078881)
65. Tsuboi J, Kawazoe K, Izumoto H, et al. Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 2008; 72 (4): 588-91 (Pubitemid 351679411)
66. Merritt JC, Niebauer M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003 Sep 15; 92 (6): 735-6 (Pubitemid 37103034)
67. Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 2008 May 7; 126 (1): 108-13 (Pubitemid 351512361)
68. Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007 Sep; 4 (9): 1170-4 (Pubitemid 47333643)
69. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45 (4): 525-30 (Pubitemid 40222245)
70. Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000; 21 (15): 1259-64 (Pubitemid 30487774)
71. Senior R, Müller-Beckmann B, DasGupta P, et al. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S117-21